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Abstract
Tumor suppressor gene CYLD is a deubiquitinating enzyme which negatively regulates various signaling pathways by
removing the lysine 63-linked polyubiquitin chains from several specific substrates. Loss of CYLD in different types of tumors
leads to either cell survival or proliferation. In this study we demonstrate that lack of CYLD expression in CYLD2/2 MEFs
increases proliferation rate of these cells compared to CYLD+/+ in a serum concentration dependent manner without
affecting cell survival. The reduced proliferation rate in CYLD+/+ in the presence of serum was due to the binding of serum
response factor (SRF) to the serum response element identified in the CYLD promoter for the up-regulation of CYLD levels.
The serum regulated recruitment of SRF to the CYLD promoter was dependent on p38 mitogen-activated protein kinase
(MAPK) activity. Elimination of SRF by siRNA or inhibition of p38 MAPK reduced the expression level of CYLD and increased
cell proliferation. These results show that SRF acts as a positive regulator of CYLD expression, which in turn reduces the
mitogenic activation of serum for aberrant proliferation of MEF cells.
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Introduction
CYLD is a deubiquitinating enzyme (DUB) which is absent or
strongly down regulated in different types of human cancer.
Cylindromatosis was the first described skin cancer caused by
mutation in the CYLD gene and subsequent loss of heterozygosity
[1]. Beside cylindromatosis, the expression of CYLD is dramat-
ically down-regulated in other types of human cancer such as
melanoma [2], cervix cancer [3], colon cancer [4,5] and multiple
myeloma [6,7]. Removal of the lysine 63 (K63) linked poly-
ubiquitin chains from different CYLD substrates including Bcl-3,
TRAF2 and TAK1 interferes and modulates different signaling
pathways such as NF-kB, JNK and p38 MAPK [8–9]. In vivo,
CYLD deficient mice were highly sensitive to chemically induced
skin tumors and developed significantly larger and faster-growing
skin papillomas [10]. This effect was attributable to the elevated
expression of cyclin D1 which caused an increase in the
proliferation rate of CYLD-deficient keratinocytes than wild-type
controls [10]. Even though previous studies has been highlighting
the importance of post translational modifications of CYLD such
as phosphorylation [11,12] and ubiquitination [13] for its tumor
suppressor function, at the present there is a lack of knowledge of
how CYLD transcription is regulated and by which signaling
pathway this regulation occurs in non-transformed primary cells.
Serum response factor (SRF) is a member of the highly conserved
MADS box family of transcription factors which regulates the
expression of immediate early genes. SRF binds to its specific
promoter sequence (CArG box), which is often located within a
slightly larger serum response element (SRE) [14,15,16]. SRF is
conserved from flies to humans and is encoded by a single gene that
is widely expressed. Functional SRF binding sites have been
identified in the promoters of many genes which encode signaling
molecules, transcription factors and many cytoskeletal components,
such as c-fos and actin. One class of SRF co-activators are activated
by the MAPK pathway in response to mitogenic and stress stimuli
[17]. A second class of SRF specific co-activators the MAL/MRTF
proteins are released from a repressive complex with G-actin upon
induced changes in actin dynamics [18]. Activated MRTF family
members inhibit cell proliferation, probably through transcriptional
up-regulation of several anti-proliferative targets [19,20,21].
Considerable alterations in the DNA binding activity of SRF upon
serum induction are either not observed or are associated with
additional events such as phosphorylation, depending on the cell
type, the stimulus and the target gene [22,23,24,25].
In the course of characterizing of the properties of mouse
embryonic fibroblasts (MEFs) derived from wild-type and
CYLD2/2 mice, we made the surprising observation that the
CYLD2/2 MEFs had elevated proliferation rate compared to
the CYLD+/+ in the presence of serum. We found a novel role for
how CYLD expression is regulated by serum through SRF
activation which caused a reduction in cell proliferation. Serum
promoted recruitment of SRF to the SRE sites located in the
CYLD promoter through p38 MAPK activation. These results
implicate reduced proliferation rate of CYLD expressing MEF
cells mediated by p38 and SRF activation, important for balancing
proliferation and homoestasis of MEF cells.
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CYLD-deficient murine embryonic fibroblasts grow much
faster than wild-type cells
Primary CYLD+/+ and CYLD2/2 MEFs, obtained from
littermate embryos were isolated (Figure 1A, upper panels) and
compared for their in vitro growth properties. To reduce the
individual variability, MEFs isolated from embryos of the same
litter and having the same genotype were pooled together and
independent pools were analyzed in different experiments. The
early-passage (P2) MEFs which were grown in the presence of
10% fetal calf serum (FCS), were found to exhibit the same
morphology (Figure 1B, left panels), spreading (Figure 1B, right
panels) and plating efficiency (Figure 1C). Surprisingly,
measurement of the growth rate of MEFs grown in the presence
of 10% fetal calf serum over a period of 96 hours showed that
CYLD deficient cells grew significantly faster than wild-type
cells using cell counting assay (Figure 1D) and expressed high
levels of cyclin D1 (Figure 1A lower panels). The same result
was obtained when three other proliferation assays (BrdU, MTS
and Almar blue) were employed or when we used later passage
of MEFs (Passage 5) (Data not shown). In accordance with the
difference in proliferation rate, we investigated the duration of
the cell cycle by using serum starvation to synchronize the cells
and then analysed cell-cycle progression after 24 hours. We
f o u n da ni n c r e a s ei nt h ea m o u n to fC Y L D +/+ cells in G1 phase
and a decrease in G2/M phase compared to the CYLD2/2
MEFs (Figure 1E). To determine whether the increase in the
proliferation rate observed in CYLD deficient cells depends on
the deubiquitinating activity of CYLD, we transiently transfect-
ed MEF cells with full-length and catalytically inactive mutant
of CYLD (CYLD
C/S). Full length CYLD but not CYLD
C/S
could significantly reduce proliferation rate of CYLD2/2
MEFs after 72 hours (Figure 1F) indicating that the deubiqui-
tinating activity of CYLD is required for the observed
phenotype.
The increases proliferation rate of CYLD2/2 MEFs is
dependent on serum concentration
As the doubling time for CYLD deficient MEF cells were
shorter compared to wild-type MEF in the presence of 10%
serum, we hypothesized that this effect might be dependent on the
concentration of serum. To investigate this, wild-type and
knockout MEFs were cultured in media with different concentra-
tions of serum (0, 1, 5 and 10%) and at different time points (24,
48, 72 and 96 h). Interestingly, we could observe no differences in
the proliferation rates (24–96 h) between the wild-type and
knockout cells in the absence of serum, nor in the presence of
1% (Figure 2A–D). Whereas, in the presence of 5% or 10% serum
significant differences in proliferation rate between wild-type and
knockout cells could be observed (Figure 2A–D). Together these
results suggest that serum contribute to the differences in the
proliferation rate between wild-type and knockout cells. The best
characterized of the cyclins that is inducible after serum induction
as initiator for the G1 phase of the cell cycle is cyclin D1. We
detected low levels of cyclin D1 in both wild-type and knockout
cells in the absence of serum (Figure 2E), whereas an accumulation
of cyclin D1 was observed in knockout compared to the wild-type
cells cultured in 10% serum (Figure 2E) supporting the phenotype
observed for the rapid growth rate in CYLD2/2 cells compared
to the wild-type cells. We have reported earlier that CYLD by
retaining Bcl-3 in the cytoplasm reduces the expression of cyclin-
D1 and consequently decreases the proliferation of keratinocytes
[10] and melanoma cells [26]. Interestingly, in the presence of
serum, we found an increase in the number of nuclear localized
Bcl-3 in CYLD2/2 cells compared to CYLD+/+ MEF cells
using confocal microscopy (Figure 2F).
Since epidermal growth factor (EGF) and lysophosphatidic
acid (LPA) in serum are strong mitotic stimuli, we investigated
proliferation properties of MEFs in the presence of these
agonists in 1% concentration of serum. Treatment with 10 ng/
ml EGF (Figure 2G) or 1 mM of LPA (Figure 2H) were unable to
increase proliferation rate of CYLD2/2 MEFs compared to
CYLD+/+. Treatment of MEFs with either 12-O-tetradeca-
noylphorbol-13 acetate (TPA) (Figure 2I) or TNF-a (Figure 2J)
which was shown earlier to regulate CYLD mediated signal
transduction [10,27], were unable to increase the proliferation
rate of CYLD2/2 MEFs compared to CYLD+/+ over a period
of 24–96 hours (Figure 2I, 2J). To ensure that the increase
proliferation observed in CYLD2/2 MEFs was not due to the
increase cell death of CYLD+/+ MEFs, we performed apoptosis
assay in the absence or presence of serum. As anticipated, in the
absence of serum more apoptotic cells could be observed
compared to cells treated with 10% of serum (Figure 3A).
Interestingly, absent or presence of serum did not induce
significant differences in the number of apoptotic cells in MEF-
CYLD+/+ compared to CYLD2/2 over a period of 24–
72 hours (Figure 3A). Since it was shown earlier that CYLD
knockdown is sensitive to TNF-a mediated apoptosis in different
transformed cell lines [27,28], here we treated CYLD+/+ and
CYLD 2/2 cells with either TNF-a,c y c l o h e x a m i d eo ra
combination of these two. Figure 3B, shows that treatment with
TNF-a, alone or in combination with cyclohexamide is unable
to affect the number of viable cells between wild-type and
knockout cells. These results suggest that loss of CYLD mediates
proliferation and not survival in MEF cells.
CYLD gene expression is regulated rapidly at the
transcriptional level by serum
To investigate whether CYLD protein level is dependent on
the concentration of serum in culture media, CYLD+/+ MEF
cells were cultured under serum deprived conditions. This
treatment resulted in a drop in the CYLD protein level
(Figure 4A) which was recovered upon serum re-addition and
peaked at approximately after 48 hours (Figure 4B, 4C). To
investigate how rapidly inducible CYLD expression occur post
serum induction, cells were serum starved for 24 hours before
serum re-addition. As early as four hours we could detect a two-
fold increase in CYLD protein levels (Figure 4D). This regulation
appeared to take place at the transcriptional level, since the
CYLD mRNA, determined by quantitative RT-PCR, dropped
after serum withdrawal and was recovered after re-addition of
serum (Figure 4E). Already after one hour serum re-addition
almost two fold CYLD mRNA could be detected (Fig 4E). To
confirm this result, cells were serum deprived before re-addition
of serum in the absence or presence of actinomycin D. This
treatment reduced CYLD mRNA (by .50 fold) and protein
(Figure 4F) both in the absence or presence of serum (Figure 4F),
suggesting that CYLD gene expression is regulated rapidly at the
transcriptional level by serum. In corroboration to this, the levels
of cyclin D1 and its mRNA stability which is dependent on the
mitogenic signaling and it is also a critical factor for actively
cycling cells in the presence of serum, showed the same pattern as
CYLD when serum was depleted (Figure 4A). As in the absence
of serum for 48 hours CYLD but not cyclin D1 could be detected
(Figure 4A), this might indicate that CYLD is a more stable
protein than cyclin D1.
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PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19613Figure 1. Increased proliferation rate of primary CYLD2/2 compared to CYLD +/+ MEFs. (A). Mouse embryonic fibroblast (MEF) protein
extracts from primary wild-type (WT) and CYLD knockout (KO) probed with antibodies against CYLD or actin. (B). Morphology (left panels) and
spreading (right panels) of CYLD-WT and KO MEF cells. (C). Plating efficiency of CYLD-WT and KO MEF cells measured as total number of adherent
cells (12 hours) expressed as the percentage of total cells plated. (D). Measurement of the growth rate of MEFs cultured in the presence of 10% fetal
calf serum (FCS) by cell counting over a period of 96 hours. (E). Cell cycle analysis of WT and KO MEFs after serum depravation (24 hours) followed by
re-addition of 10% fetal calf serum for 24 hours. (F). Cell counting of CYLD2/2 MEFs transiently transfected with mock, full length (FL-CYLD) or
catalytic inactive mutant of CYLD (C/S-CYLD) expression plasmid after 48 hours in the presence of 10% serum.
doi:10.1371/journal.pone.0019613.g001
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19613The serum regulated recruitment of SRF to the CYLD
promoter is dependent on p38MAPK activity
SRF is a transcription factor that binds to the CArG box in
immediate-early genes and activates their transcription after
serum stimulation. Analysis of the mouse CYLD promoter
revealed two potential CArG boxes (Figure 5A). Chromatin
immunoprecipitation (ChIP) assays demonstrated that SRF was
recruited to the first CArG box of the CYLD promoter at
position -1194 only when the cells were cultured in the presence
of serum, but not to the position -2284 (Figure 5B). Two well
known factors involved in activation of SRF are serum and LPA
([29,30]). Reporter gene assays using the CYLD promoter (-1297
to -1) revealed inducible activity in MEF cells, whereas mutation
of the first CArG box of the CYLD promoter at position -1194
significantly repressed CYLD promoter activity (Figure 5C).
Since serum but not LPA was able to induce proliferation of
CYLD2/2 MEFs (Figure 2G), we decided to investigate serum-
mediated SRF activation and expression. No significant changes
could be observed in the levels of SRF when wild-type and
CYLD2/2 MEFs cells were serum depleted (Figure 5D). This
might indicate that the expression level of SRF is not altered
instead activation of the SRF might be important for mediating
downstream signaling. To analyze whether SRF directly
influence the level of CYLD, we treated CYLD+/+ MEFs with
siRNA against SRF in the presence of serum and found that
reduction of SRF levels caused a significant down-regulation of
CYLD (Figure 5E). Even re-addition of serum to SRF-siRNA
treated cells was unable to restore the levels of CYLD after 48–
72 hours (Figure 5F). To investigate whether removal of SRF,
which caused reduced expression of CYLD, can mimic the
proliferation phenotype observed in CYLD2/2 MEF cells,
CYLD+/+ cells were treated with scramble or SRF-specific
siRNA. In concordance with our assumption we could show that
depletion of SRF after 48 hours caused an increase in
proliferation rate of CYLD+/+ cells compared to the control
siRNA treated cells (Figure 5G). These results together suggest
that binding of SRF to the promoter of CYLD is important for
up-regulation of CYLD, which in turn reduces proliferation of
MEF cells in the presence of serum. The proliferation and
survival of cells in response to serum is a complex network, which
integrates signals such as p38MAPK, c-Jun N-terminal kinases
(JNK), and extracellular signal-regulated kinase (ERK). To
investigate whether any of these signalling pathways can mediate
serum-induced expression of CYLD, wild-type cells were treated
with p38MAPK, ERK, and JNK specific pharmacological
inhibitors. Figure 6 demonstrates that while pre-treatment of
cells with p38MAPK inhibitor (SB203580) caused reduction in
CYLD expression levels (Figure 6A), neither ERK (PD98058,
UO126), nor JNK (SP600125) had any significant effect
(Figure 6B–C). To further analyse and monitor activation of
p38MAPK upon serum treatment, CYLD+/+ MEFs were serum
starved for 24 hours before re-addition of serum for 30, 60 and
120 minutes. This analyse revealed an initial and transient
activation of p38 at 30 and 60 minutes which declines after 120
minutes (Figure 6D). To investigate whether recruitment of SRF
to the promoter of CYLD is dependent on the activation of
p38MAPK, we treated cells with SB203580 and performed ChIP
analyses. This assay demonstrated that inhibition of p38MAPK
blocks recruitment of SRF to the promoter of CYLD in the
presence of serum (Figure 6E). As p38 directly phosphorylates
ELK1, and p38 downstream kinase MAPKAP (MK2) can
phosphorylate SRF, we decided to find whether p38 directly or
through MK2 induces CYLD gene expression. To address this
question, we performed ChIP using wild type cells in the absence
or presence of serum. Re-addition of serum to deprived cells,
recruited phospho-SRF but not phospho-ELK to the promoter of
Figure 3. Effects of TNF-a mediated apoptosis in CYLD +/+ and CYLD2/2 MEFs. (A). The apoptotic cells were analyzed by detecting the
gradual degradation of internucleosomal DNA with the DNA binding fluorescent dye propidium iodide in WT and CYLD-KO MEF cells in the absence
or presence of 10% FCS over a period of 24–96 hours. (B). The apoptotic cells were analyzed by detecting the gradual degradation of
internucleosomal DNA with the DNA binding fluorescent dye propidium iodide in WT and CYLD-KO MEF cells treated with TNF-a (100 ng/ml) for
12 hours, cyclohexamide (10 mg/ml) for 12 hours or a combination of TNF-a and cyclohexamide (100 ng/ml respective 10 mg/ml) for 12 hours.
doi:10.1371/journal.pone.0019613.g003
Figure 2. Serum concentration dependent proliferation of CYLD+/+ and CYLD2/2 primary MEFs. (A–D). Measurement of the growth
rate of MEFs by cell counting after serum withdrawal (24 hours) followed by re-addition of FCS: 0, 1, 5 and 10% over a period of 24–96 hours. (E).
Analysis of the levels of cyclin D1 and tubulin in primary CYLD+/+ compared to CYLD 2/2 MEFs in the absence (0%) or presence of 10% FCS for
48 hours. (F). Confocal plane of Bcl-3 (red) and DAPI (blue) in CYLD+/+ (upper) and CYLD2/2 (lower) MEFs after serum withdrawal (24 hours)
followed by re-addition of 10% FCS for 24 hours. (G–J). Measurement of the growth rate of MEFs by cell counting treated with serum free for
24 hours before re-addition of 1% FCS together with EGF (100 ng/ml), LPA (1 mM), TPA (100 nM) and or TNF-a (100 ng/ml) over a period of 24–
96 hours.
doi:10.1371/journal.pone.0019613.g002
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and phosphorylation of SRF is vital for upregulation of CYLD.
Furthermore, pre-treatment of CYLD+/+ MEFs with SB203580,
which is also an inhibitor of MK2, increased proliferation rate of
these cells compared to control treated cells (Figure 6G). These
results together suggest that serum is an essential factor for
p38MAPK mediated SRF activation, which in turn causes up-
regulation of CYLD at the transcriptional level. Moreover, an
increase in CYLD levels reduces the proliferation rate of MEF
cells.
Discussion
CYLD is a DUB enzyme which is lost in different types of
human cancer [8]. The tumor suppressor function of CYLD in
skin is due to the reduced proliferation rate mainly through a delay
in the G1 to S phase transition by reducing cyclin D1 expression
levels [2,10,31] in a NF-kB dependent signaling pathway. In
addition to reduced proliferation, CYLD was shown to promote
apoptosis in different cell types including HeLa [27] or HaCaT
cells [28] by interfering with NF-kB signaling pathway. Beside the
Figure 4. CYLD gene expression is regulated at the transcriptional level by serum. (A). Analysis of the levels of CYLD, cyclin D1 and tubulin
in primary CYLD+/+ MEFs in 10% FCS (control) or serum deprived cells over a period of 24–72 hours. (B–C). Analysis of the levels of CYLD and tubulin
in primary CYLD+/+ MEFs in 10% FCS (control) or serum deprived cells for 24 hours (0%) or re-addition of FCS (10%) to the cells over a period of 24–
72 hours. (D). Analysis of the levels of CYLD and tubulin in primary CYLD+/+ MEFs in 10% FCS over a period of 0.5–24 hours. (E). CYLD gene
expression by using qRT-PCR upon withdrawal (0% FCS) or re-addition of serum to the cell cultures for 1 or 4 hours. (F). Analysis of the levels of CYLD
and tubulin in primary CYLD+/+ MEFs after serum deprivation 24 hours before re-addition of 10% FCS (control) or 10% FCS together with 0.5–1.0 mg/
ml actinomycin D for 12 hours.
doi:10.1371/journal.pone.0019613.g004
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p38 MAPK signaling in a stimulus and tissue specific manner
[11,32,33,34,35,36]. Although there are studies describing differ-
ent signaling pathways regulated by CYLD during infection,
inflammation and neoplasia [8], it is not known whether and how
positive transcription regulation of CYLD on the promoter level is
Figure 5. Recruitment of SRF to the promoter of CYLD induced by serum. (A). Location of two serum response elements identified at CYLD
promoter. (B). Lysates from CYLD+/+ MEFs were examined by ChIP assay using an anti- SRF (H-300, Santa Cruz) and a PCR primer pair corresponding
to the promoter of the CYLD gene (270 bp). Immunoprecipitation (ChIP) using specific antibodies; IgG: IP using negative control rabbit
immunoglobulin; Input: 10% of the cell lysate used for the IP is shown. (C). Reporter assays revealing inducible CYLD promoter (-1297 to -1) activity in
MEF cells; (p1194SRE), whereas mutation of the consensus SRF binding site (p1194DSRE) led to reduced promoter activity. (D). Western blot analysis
of SRF and tubulin expression in the presence of 10% FCS for 48 hours (control) or cells incubated in the absence of serum over a period of 24–
72 hours (0% FBS). (E). Western blot analysis of SRF, CYLD and tubulin expression in scrambled siRNA control transfected cells or cells transfected
with the SRF siRNA nucleotides. (F). Western blot analysis of SRF, CYLD and tubulin expression in cells transiently transfected with the SRF siRNA
nucleotides after serum withdrawal (24 hours) and re-addition of FCS over a period of 24–72 hours. Control cells are transiently transfected with the
scramble siRNA nucleotides after re-addition of FCS for 48 hours. (G). Cell counting of CYLD+/+ MEFs transiently transfected with scramble or SRF
siRNA nucleotides in the presence of 10% FCS over period of 24–48 hours.
doi:10.1371/journal.pone.0019613.g005
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studied cell proliferation in MEF cells, which is an extensively
employed model for examining proliferation under normal
conditions [37]. We have found that CYLD2/2 MEFs have a
higher proliferation rates than wild-type MEFs, independent of the
passage number in culture, but depend on concentration of serum.
However, in the absence of serum, the growth retardation is
similar between CYLD+/+ and CYLD2/2 MEFs. Despite the
previous report showing that CYLD can promote apoptosis by
interfering with TNF-a signaling pathway [27,28], we did not
observe any differences in apoptotic rate under (1) non induced
condition, (2) removal of serum, (3) when the cells were treated
with TNF-a alone or (4) when treated with TNF-a together with
cyclohexamide. This indicates that absence or presence of CYLD
in primary non-transformed fibroblast is not involved in TNF-a
mediated apoptosis. The finding that concentration of serum could
Figure 6. Effects of p38MAPK inhibition to serum mediated CYLD expression. (A–C). Western blot analysis of CYLD and tubulin expression
in serum starved WT MEFs (24 hours) and readdition of 10% FCS for 24 hours in the absence or presence of SB-203580 (500 nM), PD 98058 (25 mM),
UO126 (20 mM), SP600125 (20 mM) or solvent (DMSO). (D). Western blot analysis of active and total p38MAPK in WT MEFs in the absence (24 hours) or
readdition of 10% FCS for 30, 60 or 120 minutes. (E). Lysates from CYLD+/+ MEFs were examined by ChIP assay in the absence or presence of solvent
(DMSO) or SB203580 (500 nM for 1 hour). Cells were serum starved for 24 hours and one hour before readdition of serum, SB203580 (500 nM for
1 hour) or solvent (DMSO) was added to the cell culture. Cell lysates were chromatin immunoprecipitated using anti-SRF antibody and a PCR primer
pair corresponding to the promoter of the CYLD gene was used. Immunoprecipitation (ChIP) using specific antibodies; IgG: IP using negative control
rabbit immunoglobulin; Input: 10% of the cell lysate used for the IP is shown. (F). Lysates from CYLD+/+ MEFs were examined by ChIP assay using
anti-pSRF or anti- pELK1 and a PCR primer pair corresponding to the promoter of the CYLD gene (270 bp). Immunoprecipitation (ChIP) using specific
antibodies; IgG: IP using negative control rabbit immunoglobulin; Input: 10% of the cell lysate used for the IP is shown. (G). Cell counting of CYLD+/+
MEFs in serum starved WT MEFs (24 hours) before re-addition of 10% FCS for 48 hours in the absence or presence of solvent (DMSO) or SB203580
(500 nM for 1 hour).
doi:10.1371/journal.pone.0019613.g006
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MEFs prompted us to investigate whether the levels of CYLD is
regulated by serum. Indeed removal of serum from culture media
resulted in a decrease of CYLD while re-addition of serum to the
culture media transiently increased CYLD at the protein level. To
determine whether gene transcription of CYLD can be regulated at
the RNA level we analysed by quantitative RT-PCR, the CYLD
mRNA levels upon exit and re-entry in cell cycle in response to
serum at different time points. As serum withdrawal reduced the
CYLD mRNA level already after one hour, serum re-addition
elevated CYLD mRNA significantly. These data indicates that
regulation of CYLD gene transcription is rapid in response to the
serum which regulates the context of entry and exit in cell cycle
progression. In line with this hypothesis, we found a significant
delay in G1-to-S phase progression of CYLD+/+ compared to
CYLD2/2 MEFs.
Serum response factor (SRF) is a transcription factor which
regulates the expression of immediate early genes and cytoskeletal
components through binding to its target promoter sequence,
called the CArG box. CYLD promoter analysis identified two
potential SRF binding sites, and recruitment of SRF to one of
these sites occurred in the presence of serum. Removal of serum
however, prevented/released SRF from this CArG box. In this
aspect the inducible recruitment of SRF to the CYLD promoter
may exhibit an anti-proliferative while it has been shown earlier
that SRF-dependent gene expression is essential for proliferation
in rat embryo fibroblast, myoblast and PC12 cells [38,39,40]. In
contrast to these studies, SRF depletion in mice is not affecting
proliferation of embryonic stem cell [41] or primary keratinocytes
[42]. This discrepancy could be explained by different functions of
SRF depending on the tissue/cell type in combination with the
requirement of a specific stimulus. To investigate whether the SRF
protein amount influence the serum induced CYLD expression,
we analyzed the expression pattern of SRF in the absence and
presence of serum. Since no significant differences in the levels of
SRF could be detected under normal serum condition or when
serum was removed, we decided to deplete SRF by using siRNA.
Knockdown of SRF by siRNA significantly reduced levels of
CYLD, indicating that CYLD expression is regulated by SRF.
Moreover, cell proliferation was significantly enhanced when the
cells were transfected with siRNA against SRF, compared to the
control scramble transfected CYLD+/+ cells.
Which upstream signalling is responsible for SRF-mediated
expression of CYLD in the presence of serum? Analyses of
different MAPK signalling molecules such as ERK and p38 or
JNK upon serum stimulation in MEFs demonstrated that among
these molecules, p38 activation can regulate expression levels of
CYLD. To determine whether transient activation of p38 in
CYLD+/+ MEFs can regulate expression of CYLD via SRF, we
treated the cells with p38MAPK inhibitor prior to serum addition.
This treatment completely blocked SRF recruitment to the
promoter of CYLD, and was not capable of increasing the
expression of CYLD. In accordance with these results, inactivation
of p38MAPK before addition of serum caused an increase in
proliferation rates of wild-type compared to the control treated
cells. These results suggest that serum mediated expression of
CYLD via SRF is dependent on the activation of p38MAPK,
which can in turn reduce proliferation of MEFs.
Several mechanisms have been shown to regulate SRF activity
including co-factor association, phosphorylation and regulated
nuclear translocation. In recent microarray experiments, however,
CYLD expression was not differentially regulated following
changes in actin-MAL signalling [21], and the MAL/MRTF co-
activator family is not yet known to be directly activated by
p38MAPK. Additionally, we demonstrated here that, LPA which
activates MAL-SRF dependent transcription failed to regulate
CYLD in MEFs, suggesting that CYLD induction through
p38MAPK and SRF utilizes a distinct mechanism. It has been
shown that phosphorylation by the Ca
2+-dependent CaMK
[23,43] and by p38MAPK through activation of MK2 [44] affects
DNA binding of SRF. Indeed, we could detect recruitment of
phospho-SRF to the SRE sites located in the promoter region of
CYLD, suggesting that SRF activation by p38 and MK2 are
responsible for upregulation of CYLD levels. Furthermore,
anisomycin induced activation of p38MAPK can phosphorylate
SRF, which further promotes expression of immediate early genes
[45]. An alternative possibility would involve the activation of
ternary complex factors by p38MAPK which subsequently bind
DNA cooperatively with SRF [46].
The SRF signalling pathways have been linked to proliferation,
cell survival/apoptosis or differentiation, depending on the tissue
and upstream signaling involved. In our system SRF mediated
CYLD expression acted anti-proliferative without an obvious
effect on apoptosis. It has been highlighted that SRF is not
involved in proliferation has been highlighted in flies where SRF
controls the differentiation of epithelial-derived intervein cells
during wing development [47]. Furthermore, Srf mutant mice dies
at E6.5 without any proliferative defect, instead they show lack of
differentiation [48]. In addition the impaired differentiation of
keratinocytes or SMC due to the deletion of Srf has been
previously reported [42,49]. Conversely, SRF activation by over-
expressed MRTF family members results in inhibited cell
proliferation, and the SRF co activator Myocardin is a tumor
suppressor whose expression is reduced in human tumors
[19,20,21]. In summary, our study identified SRF as a positive
regulator for expression of CYLD upon serum stimulation which
in turn reduces proliferation rate of MEF cells.
Materials and Methods
Cell culture and reagents
CYLD2/2 mice were generated as described previously [10].
Embryos were isolated at embryonic day 13.5 (E13.5). Genotyping
was performed by PCR analysis. Fibroblast cells from individual
embryos were plated and allowed to grow for 1–3 days prior to
experiments. All cultures were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (sigma) supplemented with 10% FBS, L-
glutamine (100 U/ml) and penicillin/streptomycin (100 U/ml)
and grown at 37uC with 5% CO2. All experiments were
performed in parallel using equal passage number (passage 3–5)
and a similar period in culture.
Proliferation assay
Mouse embryonic fibroblasts (MEFs) were seeded in parallel
into 24-well tissue culture plates at a density of 1610
4 cells per well
in full growth medium (DMEM plus 10% FBS). Cells were
incubated overnight, then quiesced in serum free medium (SFM)
for 48 hours before transfer to the appropriate growth-stimulatory
medium. This was either full growth medium (10% FBS) or
medium containing 0%, 1%, 5% FBS. Medium was replaced
every day and growth curves constructed over a 96 hours period
by determining cell number in quadruplicate wells using a
haemocytometer. In the growth stimulation assay, after 24 hours
incubation, the growth medium was removed, and the cells were
washed twice with PBS and then serum starved by continuing cell
culture overnight in FBS-free medium (DMEM without FBS).
Cells were either untreated (controls) or treated with 0.5% FBS
medium containing EGF (10 ng/mL or 100 ng/mL), TPA
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at 37uC for additional 24 hours.
Proliferation in the presence of different concentration of FBS
was also assessed by the MTS assay in a 96-well plate with the
density of 1610
4 cells per well and detected by the MicroELISA
plate reader (FLOU-star, bmg).
Apoptosis assay
Apoptotic cells were analyzed by detecting the gradual
degradation of internucleosomal DNA with the DNA binding
fluorescent dye propidium iodide (PI). In brief, cells in the culture
discs were fixed with freshly prepared 4% paraformaldehyde in
PBS for 4 minutes and washed three times in PBS then stained
with solution (3.5 mM Tris-HCL pH 7.6, 10 mM NaCL, 5 mg/ml
propidium iodide, 20 mg/ml RNase, 0.1% v/v NP-40) and
incubated in the dark for 20 min at room temperature. Thereafter,
cells were washed in PBS and mounted on the microscope slides
by using fluorescent mounting medium (Dako) and examined
under the fluorescence microscopy. A total number of 200 staining
cells were counted per experiment and scored for apoptosis based
on the morphology of the nuclei.
Western blot analysis
MEF cells were placed on ice and the media was aspirated. The
cells were washed once with cold phosphate-buffered saline (PBS)
and harvested in cold 16lysis buffer [50 mmol/L Tris-HCl
(pH 7.4), 150 mmol/L NaCl, 1% Triton-100, 16 protease
inhibitor mixture (1:100 dilution; Sigma)]. The whole cell lysates
were cleared by centrifugation (12 0006g for 10 min at 4uC) and
the protein content was determined. Equal amounts of protein
were loaded onto 10% polyacrylamide gels in the presence of SDS
and were separated by electrophoresis. The proteins were
transferred to polyvinylidene difluoride (PVDF) membranes,
blocked with 5% non fat dry milk in PBS for 1 hour at room
temperature and followed by overnight incubation at 4uC with
primary antibodies against CYLD [10], phospho-p38 MAP kinase
(Thr180/Tyr182), total p38 MAP kinase, phospho-JNK, total
JNK, phospho-ERK, total ERK and cyclin D1 from Cell
Signaling, serum response factor from Santa Cruz, b-actin and
a-tubulin from Sigma-Aldrich,. Membranes were imaged using
the chemiluminescence (ECL) reagents (GE Healthcare, USA).
Immunoflourescence
MEF cells were cultured on glass cover slides, rinsed twice with
PBS and fixed for 15 min using 4% paraformaldehyde in PBS,
rinsed twice and permeabilized using 0,25% Triton-X 100 in PBS
for 10 minutes. After permeabilization, the cells were washed three
times in PBS and blocked in 1% Bovine Serum Albumin (BSA) in
PBS for 1 hour. The primary antibody Bcl-3 (C-14) from Santa
Cruz was diluted 1:50 with 1% BSA in PBS and incubated with
the cells for 1 hour. A TRITC coupled anti rabbit antibody
(ab6799, Abcam) was diluted 1:2500 with 1% BSA in PBS,
staining the cells for 1 hour. Staining of the nucleus was done
using DAPI (Sigma) according to manufacturer’s instruction.
Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR)
MEFs were washed in ice-cold PBS and total RNA was
extracted from cells followed the protocol of the RNeasy
extraction kit (Qiagen). The quality of RNA was analyzed and
quantified by a NanoDrop spectrophotometer (SAVEEN WER-
NER) and used for cDNA synthesis according to the manufactur-
er’s instruction (QPCR cDNA synthesis kit; Stratagene). PCR runs
were performed in the Mx3005P real-time thermocycler (Strata-
gene) performing 40 two-step cycles consisting of 95uC for 30
seconds and 60uC for 60 seconds. The following primers were
used:
CYLD-forward 59-ACAACATGGATGCCAGGTTG-39
CYLD-reverse 59-CCGCTAATAAAGGTCCTCTG-39
b-actin-forward 59-TGTTACCAACTGGGACGACA-39
b-actin-reverse 59-GGGGTGTTGAAGGTCTCAAA-39
GAPDH-forward 59- TCGTGGATCTGACGTGCCGCC -39
GAPDH-reverse 59- CACCACCCTGTTGCTGTAGCC -39
The samples were analyzed and normalized by the MxPro
software (Stratagene).
Transient transfections and reporter gene assays
Transient transfection was performed by using PolyFect reagent
(Invitrogen) according to the manufacturer’s instructions. The
total plasmid DNA used for the transfection was 3 mg mixed with
10 ml transfection reagent per 60 mm dish. Depletion of serum
response factor were purchased from Santa Cruz. SiRNA duplexes
(2 mM) were mixed with Lipofectamine 2000 (invitrogen),
transfection reagent (50 ml) and incubated at room temperature
for 15 minutes. For each transfection, 0.8 ml siRNA transfection
mixture was added to 80% confluent cells in 60 mm dish.
Experiments were carried out 48 hours post-transfection the cells
were either counted for the proliferation assay by a haemocytom-
eter or lysed with lysis buffer for the immunoblot analysis.
The p-1194-SRE-Luciferase vector was generated using specific
primers to PCR amplify region -1297 to -1 of the CYLD gene, (-
1297 KpnI Forward: 59- AAAGGTACCGTTAAAACTGTGA-
CACAAACTCCAC-39, -1 BglII Reverse: 59- TTTAGATCT-
TGTGACAGTAACTTTCAGAACATTG-39). KpnI and BglII
digested PCR product and vector pNFkB-Luc (Stratagene Cat.
No. 631904) was ligated together. p-1194-D-SRE-Luciferase
vector was made using site directed mutagenesis kit (QuickChange
XL. Stratagene Cat. No. 200517-5) together with the following
primers; 1194-D-SRE F: 59-CCTATAGTCATATGTCATTAT-
TACATAGTAGGCTATAAACCATTTTCAAATA-39, 1194-D-
SRE R: 59-TATTTGAAAATGGTTTATAGCCTACTATG-
TAATAATGACATATGACTATAGG-39.
All cell transfection assays were repeated three times and done
in triplicates. To assay for transfection efficiency, transfections
were performed with a constant amount of Renilla expression
plasmid. Luciferase and Renilla activities were assayed 24 hours
post transfection according to the manufacturer’s (Promega)
instructions.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed using the
QuikChIP kit (IMGENEX). Briefly, MEF Cells were cross-linked
by 1% formaldehyde at 37uC for 10 min. After immunoprecip-
itation by using antibodies against SRF, (clone G-20; Santa Cruz);
phospho-Ser103-SRF (clone #4261; Cell Signaling); or phospho-
Ser383-Elk-1 (clone #9181; Cell signaling), protein-DNA cross-
links were reversed at 65uC for 4 hours. The DNA was purified
with phenol/ chloroform extraction, precipitated with EtOH and
re-suspended in DNase free water. Products were amplified by the
Mx3005P thermocycler (Stratagene) with the condition of
denaturation of 10 minutes in 95uC, followed by 35 repeats of
45 seconds at 95uC, 45 seconds at 53uC, 45 seconds at 72uC and
10 minutes at 72uC. DNA were electrophoresed through 1.5%
agarose gels and visualized through ethidium bromide staining.
The following primers were used:
CYLD/SRF-1194-forward 59-TTCTGCAACATTGCCTGA-
AC-39
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CT-39
CYLD/SRF-2284-forward 59-AAACTGTGACACAAACTC-
CACAA-39
CYLD/SRF-2284-reverse 59-CCCATCTCTTTAGGCCTC-
CT-39
Cell cycle analysis
1610
5 MEF+/+ or MEF2/2 cells per well were seeded in 6-
well plates in duplicates. The cells were synchronized for 24 hours
in serum free medium before re-addition of 10% serum. After
24 hours the cells were rinsed in PBS, trypsinized, and centrifuged
(400 rpm) for 5 minutes. Pellets were either re-suspended in 20 ml
complete medium and analyzed using ‘‘2-step cell cycle analysis’’
according to manufactures recommendation by using Nucleo-
Counter NC-300 (Chemometec) or re-suspended in 1 ml ice cold
70% EtOH and stored in 220 uC (1 hours). After hydration of the
cells, pellets were dissolved in 0,5 ml of Vindeløv solution [500 ml
DNase free water, 021 g Tris HCL (to pH 7,6) 0,025 g Propidium
iodine, 0,5 ml Nonidet P40, 9,46 g Rnase, 0,29 g NaCl] and
incubated for 20 minutes, and analyzed using FACSCalibur
(Becton-Dickinson).
Statistical analysis
Data represented are mean 6 S.D. of at least three independent
experiments. Statistical comparisons were carried out by t-test
analysis and significance was indicated by P,0.05.
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